All Stories

  1. Decoding Mitral Valve Risk in Marfan Syndrome
  2. Diagnosis and management of heritable thoracic aortic diseases
  3. The ‘Ten Commandments’ for the 2025 ESC Guidelines on Cardiovascular Disease and Pregnancy
  4. Preventing cardiovascular complications in adults with congenital heart disease: predictors and outcomes of the levels of follow-up care
  5. Translating the Latest 2025 ESC Guidelines and Consensus Statement into Acute Cardiovascular Care Practice
  6. Valve-Sparing Root Replacement in Bicuspid and Tricuspid Aortic Valves: Long-Term Outcomes Into the Second Decade
  7. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy
  8. The challenges of decision-making in managing women with prosthetic heart valves during pregnancy: a global concern
  9. How sample handling distorts telomere studies
  10. Pregnancy outcomes in women with heritable thoracic aortic disease: data from the EORP ESC registry of pregnancy and cardiac disease (ROPAC) III
  11. Systematic disruption of zebrafish fibrillin genes identifies a translational zebrafish model for Marfan syndrome
  12. Novel Aortic Dissection Model Links Endothelial Dysfunction and Immune Infiltration
  13. Differences in Arterial Events in Vascular Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome
  14. Editor's Choice – A European Delphi Consensus on the Management of Abdominal Aortic Aneurysms in Patients with Heritable Aortic Diseases
  15. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases (Translation of the shortened document prepared by the Czech Society of Cardiology)
  16. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases (Translation of the summary of the document prepared by the Czech Society of Angiology, 2025)
  17. Pregnancy with a prosthetic heart valve, thrombosis, and bleeding: the ESC EORP Registry of Pregnancy and Cardiac disease III
  18. Pregnancy-related issues in rare and low-prevalence diseases: results of ERN transversal working group on pregnancy and family planning survey
  19. Linee guida ESC 2024 per la gestione delle patologie delle arterie periferiche e dell’aorta
  20. Interpretation and classification of FBN1 variants associated with Marfan syndrome: consensus recommendations from the Clinical Genome Resource’s FBN1 variant curation expert panel
  21. Contribution of rare chromosome 22q11.2 copy number variants to non-syndromic bicuspid aortic valve
  22. Aortic and arterial manifestations and clinical features in TGFB3-related heritable thoracic aortic disease: results from the Montalcino Aortic Consortium
  23. New insights into the structural role of EMILINs within the human skin microenvironment
  24. Assessment of Myocardial Fibrosis in Marfan Syndrome Using Cardiac Magnetic Resonance Imaging
  25. Whole-exome sequencing uncovers the genetic complexity of bicuspid aortic valve in families with early-onset complications
  26. Correction: Myhre syndrome in adulthood: clinical variability and emerging genotype-phenotype correlations
  27. Rare genomic copy number variants implicate new candidate genes for bicuspid aortic valve
  28. Perinatal outcomes after in-utero exposure to beta-blockers in women with heart disease: Data from the ESC EORP registry of pregnancy and cardiac disease (ROPAC)
  29. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
  30. Myhre syndrome in adulthood: clinical variability and emerging genotype-phenotype correlations
  31. Surveillance of adults with congenital heart disease: Current guidelines and actual clinical practice
  32. Bicuspid Aortic Valve Disease with Early-Onset Complications: Characteristics and Aortic Outcomes
  33. Anterior scleral thickness in Marfan syndrome: A quantitative analysis
  34. Mitral Annular Disjunction in Heritable Thoracic Aortic Disease: Insights From the Montalcino Aortic Consortium
  35. A novel genetic mouse model of fatal aortic dissection reveals massive inflammatory cell infiltration in the thoracic aorta
  36. Bicuspid Aortic Valve Disease With Early Onset Complications: Characteristics And Aortic Outcomes
  37. Frailty and Cognitive Function in Middle-Aged and Older Adults With Congenital Heart Disease
  38. Three-dimensional co-culturing of stem cell-derived cardiomyocytes and cardiac fibroblasts reveals a role for both cell types in Marfan-related cardiomyopathy
  39. Evaluation of a nurse-led multi-component transition program for adolescents with congenital heart disease
  40. Biological Age in Congenital Heart Disease—Exploring the Ticking Clock
  41. Application of an automated analysis framework for pulsed-wave Doppler cardiac ultrasound measurements to generate reference data in adult zebrafish
  42. An Appealing Story of Sex Differences in Marfan Syndrome
  43. Unraveling the role of TGFβ signaling in thoracic aortic aneurysm and dissection using Fbn1 mutant mouse models
  44. Rare Genomic Copy Number Variants Implicate New Candidate Genes for Bicuspid Aortic Valve
  45. Refining the course: long-term outcome in patients with bicuspid aortic valve
  46. Long-term follow-up of atrioventricular valve function in Fontan patients: effect of atrioventricular valve surgery
  47. Shedding light on type B aortic dissection in Marfan syndrome: implications for patient counselling and research priorities
  48. Fluid-Structure Interaction Modeling of the Aortic Hemodynamics in Adult Zebrafish: A Pilot Study Based on Synchrotron X-Ray Tomography
  49. Preferences for disease-related information and transitional skills among adolescents with congenital heart disease in the early transitional stage
  50. Genetic Testing in Patients With Congenital Heart Disease: You Do No Harm When Using the Right Tools!
  51. Generation of human induced pluripotent stem cell line UGENTi001-A from a patient with Marfan syndrome carrying a heterozygous c.7754 T > C variant in FBN1 and the isogenic control UGENT001-A-1 using CRISPR/Cas9 editing
  52. HTAD patient pathway: Strategy for diagnostic work-up of patients and families with (suspected) heritable thoracic aortic diseases (HTAD). A statement from the HTAD working group of VASCERN
  53. Mitral Annular Disjunction: Associated Pathologies and Clinical Consequences
  54. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials
  55. Surveillance and monitoring in vascular Ehlers-Danlos syndrome in European Reference Network For Rare Vascular Diseases (VASCERN)
  56. Last year of life of adults with congenital heart diseases: causes of death and patterns of care
  57. Comparative Risks of Initial Aortic Events Associated With Genetic Thoracic Aortic Disease
  58. Cardiolaminopathies
  59. Arrhythmia and impaired myocardial function in heritable thoracic aortic disease: An international retrospective cohort study
  60. Publisher Correction: Marfan syndrome
  61. Hereditary thoracic aortic disease: How to save lives
  62. Needs and Experiences of Adolescents with Congenital Heart Disease and Parents in the Transitional Process: A Qualitative Study
  63. Association of Mitral Annular Disjunction With Cardiovascular Outcomes Among Patients With Marfan Syndrome
  64. Marfan syndrome
  65. Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes
  66. Outflow Through Aortic Side Branches Drives False Lumen Patency in Type B Aortic Dissection
  67. An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome
  68. Cardiomyopathy in Genetic Aortic Diseases
  69. Transition to adulthood and transfer to adult care of adolescents with congenital heart disease: a global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (ACNAP), the ESC Working Group on Adult Congenital Hea...
  70. Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO
  71. QRS Duration During Follow-Up of Tetralogy of Fallot: How Valuable is it? Analysis of ECG Changes in Relation to Pulmonary Valve Implantation
  72. Guía ESC 2020 para el tratamiento de las cardiopatías congénitas del adulto
  73. Congenital heart disease in the ESC EORP Registry of Pregnancy and Cardiac disease (ROPAC)
  74. Different levels of care for follow-up of adults with congenital heart disease: a cost analysis scrutinizing the impact on medical costs, hospitalizations, and emergency department visits
  75. Transfer and transition practices in 96 European adult congenital heart disease centres
  76. Pregnancy outcome in thoracic aortic disease data from the Registry Of Pregnancy And Cardiac disease
  77. Pregnancy Outcomes in Women After Arterial Switch Operation for Transposition of the Great Arteries: Results From ROPAC (Registry of Pregnancy and Cardiac Disease) of the European Society of Cardiology EURObservational Research Programme
  78. A genotype-first approach to exploring Mendelian cardiovascular traits with clear external manifestations
  79. Pathogenic variants in THSD4, encoding the ADAMTS-like 6 protein, predispose to inherited thoracic aortic aneurysm
  80. The Dynamic and Multifaceted Nature of Cardiovascular Disease and Using Genetic Testing to Inform Clinical Care: An International Perspective
  81. Genética en la cardiopatía congénita: ¿estamos preparados?
  82. The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020
  83. The ‘Ten Commandments’ in Adult Congenital Heart Disease Guidelines
  84. Myocardial disease and ventricular arrhythmia in Marfan syndrome: a prospective study
  85. Effects of fibrillin mutations on the behavior of heart muscle cells in Marfan syndrome
  86. Creating the BELgian COngenital heart disease database combining administrative and clinical data (BELCODAC): Rationale, design and methodology
  87. Myocardial Function, Heart Failure and Arrhythmia in Marfan Syndrome: A Systematic Literature Review
  88. Spontaneous Right Ventricular Pseudoaneurysms and Increased Arrhythmogenicity in a Mouse Model of Marfan Syndrome
  89. 2020 ESC Guidelines for the management of adult congenital heart disease
  90. MEK1/2 Inhibition in Murine Heart and Aorta After Oral Administration of Refametinib Supplemented Drinking Water
  91. Ambulatory Electrocardiographic Monitoring and Ectopic Beat Detection in Conscious Mice
  92. A new dimension in patent foramen ovale size estimation
  93. Pregnancy Outcomes in Women With Cardiovascular Disease: Evolving Trends Over 10 Years in the ESC Registry of Pregnancy and Cardiac Disease (ROPAC)
  94. Corrosion casting of the cardiovascular structure in adult zebrafish for analysis by scanning electron microscopy and X‐ray microtomography
  95. Long-Term Healthcare Utilization, Medical Cost, and Societal Cost in Adult Congenital Heart Disease
  96. Features of Marfan syndrome not listed in the Ghent nosology – The Dark Side of the Disease
  97. Angiotensin-II receptor blockade in Marfan syndrome
  98. Case-matched Comparison of Cardiovascular Outcome in Loeys-Dietz Syndrome versus Marfan Syndrome
  99. Development of a transition program for adolescents with congenital heart disease
  100. European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants
  101. Genetic testing for aortopathies
  102. Opinions of general and adult congenital heart disease cardiologists on care for adults with congenital heart disease in Belgium: a qualitative study
  103. Correction: Arterial tortuosity syndrome: 40 new families and literature review
  104. Sleep apnea and the impact on cardiovascular risk in patients with Marfan syndrome
  105. Genetic counselling and testing in adults with congenital heart disease: A consensus document of the ESC Working Group of Grown-Up Congenital Heart Disease, the ESC Working Group on Aorta and Peripheral Vascular Disease and the European Society of Huma...
  106. Real-world healthcare utilization in adult congenital heart disease: a systematic review of trends and ratios
  107. Disproportion and dysmorphism in an adult Belgian population with Turner syndrome: risk factors for chronic diseases?
  108. Staffing, activities, and infrastructure in 96 specialised adult congenital heart disease clinics in Europe
  109. Vascular Ehlers-Danlos Syndrome Management
  110. SMAD4 rare variants in individuals and families with thoracic aortic aneurysms and dissections
  111. Reply
  112. Body mass index in adults with congenital heart disease
  113. SMAD3 pathogenic variants: risk for thoracic aortic disease and associated complications from the Montalcino Aortic Consortium
  114. OUP accepted manuscript
  115. Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome
  116. Cardiovascular Health in Turner Syndrome: A Scientific Statement From the American Heart Association
  117. Arterial tortuosity syndrome: 40 new families and literature review
  118. Clinical history and management recommendations of the smooth muscle dysfunction syndrome due to ACTA2 arginine 179 alterations
  119. Cardiovascular imaging in Turner syndrome: state-of-the-art practice across the lifespan
  120. Clinical Validity of Genes for Heritable Thoracic Aortic Aneurysm and Dissection
  121. Hepatic Changes in the Fontan Circulation: Identification of Liver Dysfunction and an Attempt to Streamline Follow-up Screening
  122. A heart for fibrillin: spatial arrangement in adult wild-type murine myocardial tissue
  123. Predictors of Rapid Aortic Root Dilation and Referral for Aortic Surgery in Marfan Syndrome
  124. Looking for the Missing Links
  125. Tailoring the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Guidelines for the Interpretation of Sequenced Variants in the FBN1 Gene for Marfan Syndrome
  126. Heart failure and sudden cardiac death in heritable thoracic aortic disease caused by pathogenic variants in the SMAD3 gene
  127. Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome
  128. Hungarian Marfan family with large FBN1 deletion calls attention to copy number variation detection in the current NGS era
  129. Pregnancy Outcomes in Women With Rheumatic Mitral Valve Disease
  130. Propagation-based phase-contrast synchrotron imaging of aortic dissection in mice: from individual elastic lamella to 3D analysis
  131. Influence of socioeconomic factors on pregnancy outcome in women with structural heart disease
  132. Organisation of care for pregnancy in patients with congenital heart disease
  133. Sex, pregnancy and aortic disease in Marfan syndrome
  134. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting
  135. The spectrum of spontaneous coronary artery dissection: illustrated review of the literature
  136. Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial
  137. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC)
  138. The 2017 international classification of the Ehlers-Danlos syndromes
  139. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome
  140. Pregnancy in Women With SMAD3 Mutation
  141. Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome
  142. International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations
  143. FBN1 : The disease-causing gene for Marfan syndrome and other genetic disorders
  144. Risk of Pregnancy in Moderate and Severe Aortic Stenosis
  145. Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology
  146. Long-Term Outcome of Patients with Perimembranous Ventricular Septal Defect: Results from the Belgian Registry on Adult Congenital Heart Disease
  147. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology
  148. Linee guida ESC 2015 per il trattamento dell’endocardite infettiva. Task Force per il Trattamento dell’Endocardite Infettiva della Società Europea di Cardiologia (ESC)
  149. Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the European Society of Cardiology
  150. Mitral valve prolapse syndrome and MASS phenotype: Stability of aortic dilatation but progression of mitral valve prolapse
  151. Guía ESC 2015 sobre el tratamiento de la endocarditis infecciosa
  152. Clinical utility gene card for: Hereditary thoracic aortic aneurysm and dissection including next-generation sequencing-based approaches
  153. Type B aortic dissection triggered by heart transplantation in a patient with Marfan syndrome
  154. Genetic Defects in TAPT1 Disrupt Ciliogenesis and Cause a Complex Lethal Osteochondrodysplasia
  155. Marfan Syndrome and Related Heritable Thoracic Aortic Aneurysms and Dissections
  156. 2015 ESC Guidelines for the management of infective endocarditis
  157. Pregnancy in Women With a Mechanical Heart Valve
  158. Intrinsic cardiomyopathy in Marfan syndrome: results from in-vivo and ex-vivo studies of the Fbn1C1039G/+ model and longitudinal findings in humans
  159. ClinGen — The Clinical Genome Resource
  160. Marfan and Sartans: time to wake up!: Figure 1
  161. Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome
  162. Arterial hypertension in Turner syndrome
  163. Managing aortic aneurysms and dissections during pregnancy
  164. Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration
  165. Marfan Syndrome and Related Heritable Thoracic Aortic Aneurysms and Dissections
  166. Gene panel sequencing in heritable thoracic aortic disorders and related entities – results of comprehensive testing in a cohort of 264 patients
  167. Marfan Syndrome☆
  168. MAT2A Mutations Predispose Individuals to Thoracic Aortic Aneurysms
  169. The main pulmonary artery in adults: a controlled multicenter study with assessment of echocardiographic reference values, and the frequency of dilatation and aneurysm in Marfan syndrome
  170. Atenolol versus Losartan in Children and Young Adults with Marfan's Syndrome
  171. A different view on predictors of pulmonary hypertension in secundum atrial septal defect
  172. Reference Values for Echocardiographic Assessment of the Diameter of the Aortic Root and Ascending Aorta Spanning All Age Categories
  173. Loeys–Dietz syndrome is a specific phenotype and not a concomitant of any mutation in a gene involved in TGF-β signaling
  174. Treatment of pre-existing cardiomyopathy during pregnancy
  175. Absence of Cardiovascular Manifestations in a Haploinsufficient Tgfbr1 Mouse Model
  176. Relation between genotype and left-ventricular dilatation in patients with Marfan syndrome
  177. New insights into the molecular diagnosis and management of heritable thoracic aortic aneurysms and dissections
  178. Heart failure in pregnant women with cardiac disease: data from the ROPAC
  179. First report of the genetic background of Marfan syndrome in Polish patients
  180. Functional analysis of the anatomical right ventricular components: should assessment of right ventricular function after repair of tetralogy of Fallot be refined?
  181. Characterization of Cardiovascular Involvement in Pseudoxanthoma Elasticum Families
  182. Worsening in oxygen saturation and exercise capacity predict adverse outcome in patients with Eisenmenger syndrome
  183. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy
  184. Genes in Thoracic Aortic Aneurysms and Dissections - Do they Matter?: Translation and Integration of Research and Modern Genetic Techniques into Daily Clinical Practice
  185. Echocardiographic Methods, Quality Review, and Measurement Accuracy in a Randomized Multicenter Clinical Trial of Marfan Syndrome
  186. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy
  187. Novel MYH11 and ACTA2 mutations reveal a role for enhanced TGFβ signaling in FTAAD
  188. Thoracic aortic-aneurysm and dissection in association with significant mitral valve disease caused by mutations in TGFB2
  189. Predictive model for late atrial arrhythmia after closure of an atrial septal defect
  190. Aneurysm-osteoarthritis syndrome with visceral and iliac artery aneurysms
  191. Multiple Aneurysms in a Patient With Aneurysms-Osteoarthritis Syndrome
  192. Twenty patients including 7 probands with autosomal dominant cutis laxa confirm clinical and molecular homogeneity
  193. In-Frame Mutations in Exon 1 of SKI Cause Dominant Shprintzen-Goldberg Syndrome
  194. Comprehensive molecular analysis demonstrates type V collagen mutations in over 90% of patients with classic EDS and allows to refine diagnostic criteria
  195. Aggressive Cardiovascular Phenotype of Aneurysms-Osteoarthritis Syndrome Caused by Pathogenic SMAD3 Variants
  196. The Ghent Marfan Trial — A randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers
  197. Right Ventricular Function in Patients With Eisenmenger Syndrome
  198. Questioning the Pathogenic Role of the GLA p.Ala143Thr “Mutation” in Fabry Disease: Implications for Screening Studies and ERT
  199. Phenotypic spectrum of the SMAD3-related aneurysms–osteoarthritis syndrome
  200. The importance of pulmonary artery pressures on late atrial arrhythmia in transcatheter and surgically closed ASD type secundum
  201. Applying massive parallel sequencing to molecular diagnosis of Marfan and Loeys-Dietz syndromes
  202. A Quantitative Comparison Between Baseline Hemodynamics and End-Stage Aneurysm Formation in ApoE −/− Mice
  203. The new Ghent criteria for Marfan syndrome: what do they change?
  204. An Integrated Framework to Quantitatively Link Mouse-Specific Hemodynamics to Aneurysm Formation in Angiotensin II-infused ApoE −/− mice
  205. Iron deficiency is associated with adverse outcome in Eisenmenger patients
  206. PREDICTING THE OCCURRENCE OF ATRIAL ARRHYTHMIA AFTER CLOSURE OF AN ATRIAL SEPTAL DEFECT
  207. Resolving in-vivo flow fields in the systemic circulation of the mouse through combined ultrasound imaging and computational fluid dynamics
  208. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial
  209. Dilated cardiomyopathy caused by a novel TNNT2 mutation—Added value of genetic testing in the correct identification of affected subjects
  210. Cardiovascular manifestations in men and women carrying a FBN1 mutation
  211. Short stature, severe aortic root dilation, skin hyperextensibility, extreme joint laxity and craniofacial dysmorphic features: a probable new syndrome
  212. The revised Ghent nosology for the Marfan syndrome
  213. Expanding the phenotype of sudden cardiac death—An unusual presentation of a family with a Lamin A/C mutation
  214. The Belgian Eisenmenger syndrome registry: Implications for treatment strategies?
  215. Circulating Transforming Growth Factor-β in Marfan Syndrome
  216. Patient-Specific Modelling of Aortic Arch Wall Shear Stress Patterns in Patients With Marfan Syndrome
  217. Short-term systolic and diastolic ventricular performance after surgical ventricular restoration for dilated ischemic cardiomyopathy
  218. Pathogenic FBN1 mutations in 146 adults not meeting clinical diagnostic criteria for Marfan syndrome: Further delineation of type 1 fibrillinopathies and focus on patients with an isolated major criterion
  219. Marfan and Marfan-like syndromes
  220. Clinical and Molecular Study of 320 Children With Marfan Syndrome and Related Type I Fibrillinopathies in a Series of 1009 Probands With Pathogenic FBN1 Mutations
  221. Strain Rate Imaging Detects Early Cardiac Effects of Pegylated Liposomal Doxorubicin as Adjuvant Therapy in Elderly Patients with Breast Cancer
  222. Comprehensive clinical and molecular assessment of 32 probands with congenital contractural arachnodactyly: Report of 14 novel mutations and review of the literature
  223. Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24–32 mutation
  224. The expanding cardiovascular phenotype of Marfan syndrome
  225. A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients
  226. Absence of arterial phenotype in mice with homozygous slc2A10 missense substitutions
  227. Effect of an Abdominal Aortic Aneurysm on Wave Reflection in the Aorta
  228. Successful alcohol septal ablation for late recurrence of left ventricular outflow tract obstruction after surgical myectomy in hypertrophic obstructive cardiomyopathy
  229. Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands
  230. Arterial tortuosity syndrome: clinical and molecular findings in 12 newly identified families
  231. Effect of Mutation Type and Location on Clinical Outcome in 1,013 Probands with Marfan Syndrome or Related Phenotypes and FBN1 Mutations: An International Study
  232. Utility of molecular analyses in the exploration of extreme intrafamilial variability in the Marfan syndrome
  233. The Impact of an Abdominal Aortic Aneurysm on Aortic Wave Reflection
  234. Early Surgical Experience With Loeys-Dietz: A New Syndrome of Aggressive Thoracic Aortic Aneurysm Disease
  235. Marfan Syndrome
  236. Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood
  237. Experimental and numerical assessment of the impact of abdominal aortic aneurysms on arterial wave reflection
  238. Synergistic inhibition of the enzymatic activity of aminopeptidase N by divalent metal ion chelators
  239. Primary impairment of left ventricular function in Marfan syndrome
  240. Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor
  241. A critical analysis of minor cardiovascular criteria in the diagnostic evaluation of patients with Marfan syndrome
  242. Aortic reflection coefficients and their association with global indexes of wave reflection in healthy controls and patients with Marfan's syndrome
  243. Variability of aortic stiffness is not associated with the fibrillin 1 genotype in patients with Marfan's syndrome
  244. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome
  245. Echocardiographically estimated left ventricular end-diastolic and right ventricular systolic pressure in normotensive healthy individuals
  246. The use of Tissue Doppler Imaging for the assessment of changes in myocardial structure and function in inherited cardiomyopathies
  247. Effects of age, gender, and left ventricular mass on septal mitral annulus velocity (E′) and the ratio of transmitral early peak velocity to E′ (E/E′)
  248. Evaluation of left ventricular dimensions and function in Marfan's syndrome without significant valvular regurgitation
  249. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2
  250. Comprehensive molecular screening of theFBN1gene favors locus homogeneity of classical Marfan syndrome
  251. Functional analysis of the common carotid artery
  252. DUP25 remains unconfirmed
  253. Familiale aandoeningen van de thoracale aorta
  254. Diastolic dysfunction, infarct size, and exercise capacity in remote myocardial infarction: a combined approach of mitral E-wave deceleration time and color M-mode flow propagation velocity
  255. Parameters of inflammation and infection in a community based case-control study of coronary heart disease
  256. QT dispersion is not related to infarct size or inducibility in patients with coronary artery disease and life threatening ventricular arrhythmias
  257. Connective Tissue Disorders